The very low-density lipoprotein (VLDL) receptor is a member of the low-density lipoprotein (LDL) receptor family. In vitro and in vivo studies
Introduction
The low-density lipoprotein (LDL) receptor family is a growing receptor family composed of more than ten receptors. LDL receptor, a genetic defect of which induces familial hypercholesterolemia (FH), has been discovered and elucidated as an LDL receptor pathway (1, 2) . Plasma LDL particles are recognized, internalized and degraded by the coated pit-located hepatic LDL receptors. FH heterozygotes (about 1 per 500 people) express half of the normal number of functional LDL receptors, and rare FH homozygotes (about 1 per million people) express few to no functional LDL receptors on their cell surface. Their plasma cholesterol levels rise from 300 to 500 mg/dl, and 600 to 1200 mg/dl, respectively. Even though the physiological functions of LDL receptor have been established, the functions of other LDL receptor family members are under investigation. In the LDL receptor family, the very l o w -d e n s i t y l i p o p r o t e i n ( V L D L ) r e c e p t o r a n d apolipoprotein (apo) E receptor 2 (apoER2) are most similar to the LDL receptor structurally (3) . In this review, we describe a special feature of the VLDL receptor as a peripheral lipoprotein receptor.
Characterization of the VLDL Receptor

Cloning of the VLDL receptor
In 1998, Herz et al. cloned LDL receptor-related protein-1 (LRP-1), which is the second protein of the LDL receptor family from the human liver cDNA library (4) . Its protein is a large cell surface protein containing 4,544 amino acids (to 600 kDa) and consists of five common structural domains resembling those of LDL receptor: (i) ligand-binding type cysteine-rich repeats (ii) epidermal growth factor (EGF) receptor-like cysteine-rich repeats (iii) YWTD domains (iv) a single membrane-spanning segment, and (v) a cytoplasmic domain. LRP-1 binds apoEcontaining lipoproteins but not LDL, and functions as a remnant lipoprotein receptor in the liver in cooperation with LDL receptor. Recently, novel functions on amyloid β-protein and tissue-type plasminogen activator (tPA) in the brain also have been elucidated (5, 6) .
At that time, we considered that LRP-1 was too large of a protein and speculated that another lipoprotein receptor would have a sequence and structure more similar to those of LDL receptor. To exclude the rabbit LDL receptor, the entire pooled cDNA library was digested with Sal I and recircularized with T4 DNA ligase. The presence of a unique Sal I site in the rabbit LDL receptor cDNA and the Okayama-Berg vector resulted in the loss of any LDL r e c e p t o r c D N A s a f t e r r e c i r c u l a r i z a t i o n a n d retransformation. The resulting LDL receptor-subtracted cDNA library was screened with the 1.9-kb Sma I-Sal I fragment from the rabbit LDL receptor cDNA under lowstringency hybridization conditions (7, 8) . Surprisingly, a cloned new cDNA encoded a protein with striking homology to the LDL receptor (Fig. 1) . We considered that the new gene was a brother of the LDL receptor but LRP-1 was a distant relative. The mature protein consisted of five domains spanning 846 amino acids: 328 N-terminal amino acids including an 8-fold repeat of 40 amino acids homologous to the ligand binding repeat of the LDL receptor; 396 amino acid residues homologous to the epidermal growth factor precursor including three cysteinerich repeats; a region immediately outside of the plasma membrane, rich in serine and threonines; 22 amino acids transversing the plasma membrane; and 54 amino acids including the NPVY sequence required for clustering of the LDL receptor in coated pits and that projects into the cytoplasm. Following the rabbit VLDL receptor cDNA cloning, we also cloned the human VLDL receptor cDNA from the THP-1 monocytic leukemia cell cDNA library (9) . The human VLDL receptor gene contains 19 exons spanning approximately 40 kb. The exon-intron organization of the gene is almost the same as that of the LDL receptor gene, except for an extra exon that encodes an additional repeat in the ligand-binding domain (LDL receptor contains a 7-fold repeat and VLDL receptor has an 8-fold repeat). The VLDL receptor mRNAs produce two kinds of VLDL receptor proteins by alternative splicing type 1 VLDL receptor and type 2 VLDL receptor, which lacks the O-linked sugar domain encoded by exon 16. Although the structure and organization of the VLDL receptor gene is highly similar to those of the LDL receptor gene, the two genes are located on different chromosomes: the LDL receptor gene is on chromosome 19 and the VLDL receptor gene on chromosome 9.
Tissue distribution
The VLDL receptor mRNAs are highly abundant in the heart, muscle, adipose tissue, and brain, and are barely detectable in the liver, in which the LDL receptors are expressed abundantly (7) . We also confirmed the VLDL receptor expression in THP-1 cells, PMA-induced (THP-1) macrophages, HL-60 cells, human monocyte-derived macrophages, rabbit alveolar macrophages and rat cultured cardiomyocytes (9) (10) (11) (12) (13) . Immunoreactive VLDL receptor protein was detected in the endothelium of the capillaries and small arterioles but not in the veins or venules of bovine skeletal muscle, heart, ovary and brain. The VLDL receptor was also detected at high levels on the endothelial surface of bovine coronary arteries but not in the aortic endothelium (14) . Interestingly, the type 1 VLDL receptor containing the O-linked sugar domain was preferentially expressed in the heart, brain, and skeletal muscle, whereas bovine aortic endothelial cells expressed only type 2 VLDL receptor (15) . In human and rabbit atherosclerotic lesions, the VLDL receptor was expressed in macrophages and smooth muscle cells, and its expression was highly induced in atherosclerotic lesions (16) (17) (18) (19) . The VLDL receptor is most abundantly expressed in the heart. An in situ hybridization study revealed that VLDL receptor mRNA was detected within the human myocardium, and the hybridization pattern corresponded to that of myofibrils. In the human liver, the presence of VLDL receptor mRNA was only detected within vascular structures and sinusoidal lining cells (Kuppfer cells), with no signal detected in hepatocytes (16) . In the human brain, the VLDL receptor was present on resting and activated microglia associated with senile plaques and cortical neurons. A novel splicing variant lacking exon 4 in the cysteine-rich repeats region was discovered by RT-PCR more often than type 1 and type 2 VLDL receptors, only in the brain (20) .
Ligand-binding specificity of the VLDL receptor as a lipoprotein receptor
To confirm the ligand-binding specificity of the new cloned gene that was similar to the LDL receptor structurally, we transfected the cloned cDNA into ldlA-7 cells (LDL receptor-deficient CHO cells) and examined the ligand-binding specificity compared to that of LDL receptor transfectants. The new gene produced proteins that bound apoE-containing lipoproteins including VLDL, intermediate density lipoprotein (IDL) from Watanabe heritable hyperlipidemic (WHHL) rabbits and β-migrating VLDL (β-VLDL) from cholesterol-fed rabbits, but did not bind LDL from WHHL rabbits, whereas CHO cells transfected with the human LDL receptor cDNA bound both apoB-and apoE-containing lipoproteins including VLDL, IDL, LDL from WHHL rabbits and β-VLDL from cholesterol-fed rabbits.
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I-labeled β-VLDL binding to the transfected cells was inhibited by unlabeled apoE-liposomes, indicating that the receptor recognizes apoE (7, 8) . These binding properties were confirmed by a more detailed examination which indicated that the VLDL receptor never bound LDL. The VLDL receptor was more slowly processed than the LDL receptor, and did not show the increase in affinity and decrease in binding of β-VLDL on cooling to 4 degrees that was exhibited by the LDL receptor (21) . On the other hand, the VLDL from fasted normal human subjects bound with lower affinity than the VLDL prepared from WHHL rabbits or the β-VLDL from cholesterol-fed rabbits. A ligand blot study clearly showed that human VLDL receptor bound β-VLDL from fasted cholesterol-fed rabbits with higher affinity than human fasted VLDL particles ( Fig. 2A) , and cold LDL completed 125 I-β-VLDL binding to the LDL receptor protein but not to the VLDL receptor protein (Fig. 2B) . The low affinity binding of fasted human VLDL to the VLDL receptor could be overcome by enriching VLDL with either apoE or lipoprotein lipase (LPL) (22) . There are three mechanisms between LPL and the VLDL receptor: (i) directly binding to the VLDL receptor through LPL, (ii) mediating the TG-rich lipoprotein particles through heparan sulfate proteoglycans, and (iii) its lipolytic activity, converting VLDL particles to smaller remnants (apoE-rich particles) before they can become endocytosed by VLDL receptor through apoE. Fluorescence microscopic examination indicated that Pseudomonas LPL that was dissimilar to human LPL structurally, but had a lipolytic activity, directly enhanced the binding of the fasted human VLDL to the VLDL receptor (Fig. 3) . We consider that the third mechanism is the most important factor in VLDL receptor binding specificity. Niemeier A et al. showed the same mechanism for chylomicron particles. The VLDL receptor mediated the uptake of chylomicron remnant (CR), and this uptake was further increased by the addition of apoE and inactivated LPL (23) . Taking into account that the VLDL receptor and LPL are expressed in the same tissues, these findings suggest that the metabolism of IDL (VLDL remnant) and CR could be mediated by the VLDL receptor in peripheral fatty acid-active tissues, in concert with LPL (3).
Type III hyperlipoproteinemia is a genetic lipid disorder that is characterized by the accumulation of cholesterol-rich CR and hepatic β-VLDL. Most patients of type III hyperlipoproteinemia are homozygous for a mutant form of apoE (apoE2/2, Arg158-Cys) that is not recognized by hepatic LDL receptors. We performed a competition study for binding with β-VLDL using VLDL derived from normolipidemic human subjects, homozygous for either apoE3/3 or apoE2/2, in LDL receptor-deficient CHO cells expressing the human VLDL receptor. In contrast to the LDL receptor, VLDL receptor bound apoE 2/2 VLDL or apoE 3/3 VLDL identically in vitro (24) . Furthermore, adenovirus-mediated VLDL receptor expression in the liver of apoE2/2 and apoE3-Leiden transgenic mice lowered cholesterol levels, indicating that the VLDL receptor recognized apoE2/2 and apoE3-Leiden. The reduction in plasma cholesterol was mainly due to a reduction in the VLDL levels (25) .
Lp (a) is a major inherited risk factor associated with premature heart disease and stroke. Strickland and colleagues (18) demonstrated that Lp (a) was recognized by the VLDL receptor, and clearance of Lp (a) was delayed in VLDL receptor-deficient mice. At the moment, the lipoproteins recognized by the VLDL receptor are VLDL, IDL (VLDL remnants), CR, and Lp (a).
Regulation of the VLDL receptor expression
When a cell takes up LDL particles into the cytoplasm through LDL receptor, three steps act to stabilize the cell's cholesterol content: (i) a suppression of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase gene (a key enzyme for de novo cholesterol synthesis) and acceleration of the degradation of the enzyme protein, (ii) an activation of Acyl-CoA: cholesterol acyltransferase (ACAT), a cholesterol-esterifying enzyme, to protect cells from free cholesterol, and (iii) a suppression of the LDL receptor own gene (a key lipoprotein receptor taking up plasma cholesterol). It has been accepted that the LDL receptor is down-regulated by intracellular lipoproteins. We first reported that the VLDL receptor is not down regulated by sterols in THP-1 and rabbit resident alveolar macrophages (9, 10) . Western blots also showed that the LDL receptor protein disappeared when 100 µg/ml of β-VLDL was added to the medium for 48 hours, but the VLDL receptor protein level was not changed in THP-1 cells (Fig. 4) . There is a sterol regulatory element (SRE)-1 in the human LDL receptor gene and two SRE-1-like sequences in the VLDL receptor gene (9) . SRE-1 contains a direct repeat of the nucleotide sequence CAC on the same DNA strand, separated by two Cs. The two CAC sequences are considered to be the target of SREbinding protein 1, which controls transcription of the LDL receptor gene. The SRE-1-like sequences in the VLDL receptor contain single nucleotide substitutions that disrupt the direct CAC repeats. This might be the reason why VLDL receptor expression is not regulated by intracellular lipoproteins.
In addition, a fasted state induced high VLDL receptor expression in the heart and low expression in the fat in mice, even though the expression in rats was not changed by a 48-hour fasting state (26, 27) . We also confirmed that, in Balb/c mice fasted for 48 hours, VLDL receptor as well as LPL, fatty acid translocase (FAT)/CD36, hearttype fatty acid-binding protein (H-FABP), acyl-CoA synthetase (ACS) and long chain acyl-CoA dehydrogenase (LCAD) mRNAs, as fatty acid metabolism indicators, increased. Pyruvate kinase (PK) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNAs, as glucose metabolism indicators, did not change. Electron microscopic examination indicated that the lipid droplets accumulated in the hearts of Balb/c mice fasted for 48 hours. During the development of SD (Sprague-Dawley) rats, VLDL receptor, LPL, FAT/CD36, H-FABP, ACS and LCAD mRNAs increased gradually with growth. However, PK and GAPDH mRNAs did not show this tendency. In cultured neonatal rat cardiomyocytes, VLDL receptor expression increased with days in culture, which was compatible with the in vivo results. Oil red-O staining showed cardiomyocytes after 7 days in culture (when the VLDL receptor protein is present) had accumulated β-VLDL. There were no detectable LDL receptor mRNAs in cultured neonatal rat cardiomyocytes, showing that remnant lipoproteins (β-VLDL) are taken up by the myocardium through the VLDL receptor (13) . Triglyceride hydrolysis by LPL results in the generation of free fatty acids, 2-monoglycerol and remnant lipoprotein particles (IDL and CR). The resultant fatty acids are transported across the plasma membrane into the heart by simple diffusion and membrane-associated transporters (FAT/ CD36, FATP and FABPpm). On the other hand, remnant lipoprotein particles are also taken up into the heart by the VLDL receptor.
Thyroid hormone was a positive regulator of the VLDL receptor in rat skeletal muscle but not in the fat or heart (27) . VLDL receptor expression in rabbits is up-regulated by estrogen in the heart and down-regulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) in muscle (28, 29) . In JEG-3 and BeWo choriocarcinoma cells, two trophoblast-derived cell lines, 8-bromo-cAMP suppressed VLDL receptor expression. On the other hand, insulin and clofibrate (hypolipidemic drugs) upr e g u l a t e d V L D L r e c e p t o r e x p r e s s i o n . 2 5 -hydroxycholesterol did not lead to sterol negative feedback on VLDL receptor expression (30) . The VLDL receptor mRNA in adipose tissue and muscle was increased by 14-day gemfibrozil treatment in rabbits, indicating that the enhanced VLDL receptor expression was one of the mechanisms of the lipid-lowering effect of fibrate (31) . IFN (Interferon)-γ inhibited VLDL receptor expression in PMA-treated THP-1 cells (monocytes), HL-60 cells and human monocyte-derived macrophages. However, this effect was not observed in normal THP-1 cells (12) .
In contrast with the non-sterol regulation of VLDL receptor expression in vitro, Tiebel et al. (32) examined dietary regulation of the VLDL receptor in C57BL/6, LDL receptor knockout (LDL-R-/-), apoE knockout (apoE-/-) and LDL receptor/apoE double knockout (LDL-R-/-; apoE-/-) mice. VLDL receptor mRNA expression was down-regulated 3-fold by administrting an atherogenic diet, in the heart and skeletal muscle only, in LDL-R-/-mice. VLDL receptor mRNA was up-regulated by an atherogenic diet in the adipose tissue in all models except LDL-R-/-; apoE-/-mice. These findings suggest that SRE-1-like sequences in the VLDL receptor gene may be functional in the heart and skeletal muscle when LDL receptor is absent, and that apoE is required for regulation of VLDL receptor expression.
Reliable evidence of VLDL receptor as a lipoprotein receptor in vivo
In 1996, a conflicting report using VLDL receptor knockout (VLDL-R-/-) mice to study VLDL receptor as a lipoprotein receptor was published. VLDL-R-/-mice did not show any lipoprotein abnormality, although the adipose tissue mass of VLDL-R-/-mice was reduced (33) . On the other hand, gene expression of the VLDL receptor in the liver declined plasma cholesterol levels in various laboratories (25, (34) (35) (36) . We suggested that the tissue distribution of VLDL receptor might be a reason why VLDL receptor deficiency did not induce lipoprotein abnormality and why the plasma lipoprotein level was controlled by lipoprotein receptors in the liver. In 2000, Tacken et al. (37) elegantly solved this problem and demonstrated that the VLDL receptor is a peripheral lipoprotein receptor for VLDL triglycerides in vivo. They created VLDL receptor/LDL receptor double knockout (VLDL-R-/-; LDL-R-/-) mice and VLDL receptor over-expressing on LDL receptor knockout (LDL-R-/-) mice. When the mice were fed a high-fat diet, a lack of the VLDL receptor (VLDL-R-/-; LDL-R-/-) resulted in a significant increase in the serum triglyceride levels, and over expression of the VLDL-R resulted in a significant decrease in the serum triglyceride levels, compared to those in the LDL-R-/-mice. Furthermore, a period of prolonged fasting with a chow diet showed a significant increase in serum triglyceride levels in VLDL-R-/-; LDL-R-/-mice compared to those in LDL-R -/-mice. These data indicate that the plasma lipoprotein level in mice strongly depends on LDL receptor in the liver, and LDL receptor disguised the effect of VLDL receptor on lipoprotein metabolism.
Multiple Functions
Gene therapy for familial hypercholesterolemia and apoE mutants
The adenovirus-mediated transfer of the VLDL receptor gene into LDL receptor knockout mice liver greatly enhanced the ability to clear the IDL fraction, resulting in a marked lowering of the plasma IDL/LDL fraction (34, 35) . Moreover, helper-dependent adenovirus-mediated delivery of VLDL receptor into hepatocytes produced the long-term lowering of plasma cholesterol and prevented atherosclerosis development in LDL receptor knockout mice (36) . Gene therapy using VLDL receptor instead of LDL receptor for familial hypercholesterolemia (FH) is reasonable, because the normal LDL receptor might be recognized as a foreign protein in FH patients. VLDL receptor is non-immunogenic because it is normally expressed in fatty acid-active tissues, even in FH patients. Gene therapy using VLDL receptor has a possibile use in the treatment of apoE mutants, because VLDL receptor binds apoE2/2 and apoE3-Leiden (25) . As yet there has been no report of gene therapy using VLDL receptor for human FH or apoE mutants.
Metabolic syndrome/atherosclerosis and the VLDL receptor
Metabolic syndrome is characterized by a cluster of obesity, insulin resistance, hypertension, and atherogenic dyslipidemia, and is associated with increased risk of coronary heart disease. It seems that VLDL receptor is involved in the mechanism of metabolic syndrome because VLDL receptor knockout (VLDL-R-/-) mice revealed a modest decrease in adipose tissue mass (33) , and a higher affinity ligand of the VLDL receptor is remnant lipoprotein (3). Recently, Goudriaan et al. (38) reported that VLDL-R-/-mice remained lean and did not have insulin resistance after 17 weeks of a high-fat, high-calorie (HFC) diet compared to wild-type mice, and the weight gain of VLDL-R-/-on ob/ob mice was less profound compared with that of ob/ob mice. Moreover, VLDL receptor deficiency led to increased plasma triglyceride after HFC feeding. These data indicated that inhibition of VLDL receptor expression in adipose tissue may be a therapeutic strategy for obesity. VLDL receptor expression, primarily in macrophages, has been confirmed in human and rabbit atherosclerotic lesions (16) (17) (18) (19) . In addition, we reported that IFN-γ inhibited VLDL receptor expression and foam cell formation in three human macrophages (PMA-induced THP-1, PMA-induced HL-60 and human monocyte-derived macrophages) by β-VLDL, which is a representative lipoprotein in metabolic syndrome and type III hyperlipoproteinemia (12) . These data showed that VLDL receptor might be a macrophage β-VLDL receptor, which is one of the receptors for macrophage foam cell formation. However, controversial findings using a mouse model in vivo have been reported. Yagyu et al. (39) showed that atherosclerosis was not different between HuB (human apo B) transgenic mice and VLDL receptordeficient HuB transgenic mice after 4 months of an atherogenic diet. Tacken et al. (40) also showed that neither VLDL receptor deficiency nor endothelial VLDL receptor over expression affected the atherosclerotic lesion size. Interestingly, they indicated that deficiency for the VLDL receptor profoundly increased intimal thickening after vascular injury. We were not able to detect a sufficient amount of VLDL receptor expression in mouse peritoneal macrophages or J774 mouse macrophage cells (data not shown). At this time, we do not have any data to explain this difference between humans and mice.
Reelin signaling and the VLDL receptor
In 1999, we encountered an impact paper from Herz and colleagues (41) showing that the absence of both apoER2 and VLDL receptor in mice led to an inversion of cortical layers and the absence of cerebellar foliation. This phenotype is similar to that seen in animals carrying a mutation in either the reelin gene or the disabled-1 (Dab-1) gene. Both VLDL receptor and apoER2 can bind reelin on their extracellular domains, which subsequently induces the tyrosine phosphorylation of Dab-1 (42, 43) . Dab-1 not only binds to the Asn-Pro-Xxx-Tyr (NPxY; where x denotes any amino acid) sequences in the cytoplasmic domain of both apoER2 and VLDL receptor, but also binds to those of the LDL receptor and LRP-1 (41) . The NPVY sequence in LDL receptor has been accepted as a coated pit signal sequence, but these findings opened a new era of signaling research on the LDL receptor family (44) .
Novel functions of VLDL receptor
In addition to apoE and LPL (7, 8, 22, 45) , VLDL receptor binds receptor-associated protein (RAP) (46) , thrombospondin-1 (47), urokinase plasminogen activator (uPA)/plasminogen activator inhibitor-1 complex (45, 48) , several other proteinase-serpin complexes (49) , and tissue factor pathway inhibitor (TFPI) (50) . More recently, it has been reported that a 23-amino acid fragment of TFPI localized to the C-terminus mediated the VLDL receptor, and they showed that the VLDL receptor might be involved in angiogenesis and tumor growth (51) . Early study using VLDL receptor-transfected COS-7 cells indicated that cell growth was inhibited by the VLDL receptor, and this growth inhibition was ligand-independent (52) . VLDL receptor knockout mice were always segregated with the retinal angiogenesis and subretinal neovascularization (53) . On the other hand, it seems that endothelial cells are important sites for VLDL receptor because the movement of active LPL across endothelial cells involves both heparan sulfate proteoglycan and VLDL receptor, and VLDL receptor knockout mice showed lower plasma LPL activity, though the exact mechanism is under investigation (37, 54) .
Beyond the function of VLDL receptor as a peripheral lipoprotein receptor, the possibilities of its physiological function have been extended to include signal transduction, angiogenesis and tumor growth.
